Premier Alternatives

PhotoPharmics

Lehi, UT · Founded 2011 · Privately Held (backing)

Developer of non-invasive therapies designed to improve the lives of patients suffering from neurological disorders and addictions. PhotoPharmics is based in Lehi, UT and was founded in 2011. It was valued at $51.8 million at its later-stage round in Nov 2025, the last priced event on record. It has raised $50.9 million across 8 recorded rounds; the latest was a $26.2 million early-stage round in Oct 2023.

PMV mark · valuation
$51.8M
Oct 2026
Priced at
its later-stage round
Nov 2025
Total raised
$50.9M
Last round
Early Stage VC
Oct 2023

PhotoPharmics key facts

as of Oct 2026
  • Developer of non-invasive therapies designed to improve the lives of patients suffering from neurological disorders and addictions.
  • PhotoPharmics is valued at approximately $51.8M as of Oct 2026, set at its later-stage round, Nov 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $50.9M across 8 recorded rounds; the latest was Early Stage VC ($26.2M) in Oct 2023.
  • Notable investors include MedTech Innovator, National Institutes of Health, Kickstart (US), Frazier Group, Angel Star Ventures — 13 tracked in total.
  • PhotoPharmics has filed 9 Form Ds with the SEC since 2012, most recently Apr 2025 ($23.9M sold to 27 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
MEDIUM confidence
$51.8M

Valued at $51.8M at its later-stage round, Nov 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of PhotoPharmics with a free account
  • ·The complete investor list: 13 names
  • ·Watch PhotoPharmics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

PhotoPharmics funding rounds

8 rounds
Oct 2023Early Stage VC$26.2MSEC filing▮
Dec 2020Seed Round$2.5MSEC filing▮
Sep 2019Early Stage VC$6.6MSEC filing▮
Feb 2017Debt$2.7MSEC filing▮
Jan 2017Seed Round$2.3MSEC filing▮
Full funding history →

PhotoPharmics valuation

PhotoPharmics was valued at $51.8 million at its later-stage round in Nov 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has PhotoPharmics raised?

PhotoPharmics has raised $50.9 million across 8 recorded rounds since 2012. The largest was a $6.6 million early-stage round in Sep 2019; the most recent was a $26.2 million early-stage round in Oct 2023.

PhotoPharmics has filed 9 Form Ds with the SEC since 2012, most recently in Apr 2025 ($23.9 million sold to 27 investors).

PhotoPharmics investors

13 investors are on record for PhotoPharmics, including MedTech Innovator, National Institutes of Health, Kickstart (US) and Frazier Group. The early-stage round in Oct 2023 drew 47 investors.

About PhotoPharmics

Developer of non-invasive therapies designed to improve the lives of patients suffering from neurological disorders and addictions. The company's therapies offer chrono-biological treatments for Parkinson's disease, and a medical edge-lit device used to treat neurological disorders, enabling medical institutions to restore the health of patients suffering from Parkinson's disease.

Sector
Healthcare
HQ
Lehi, UT, United States
Founded
2011
Employees
9
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.